Northern Institute for Cancer Research

Staff Profile

Dr David Jamieson

Research Associate


  • BSc (Hons), Biomedical Sciences, Northumbria University.
  • PhD, Newcastle University.


Administrative responsibilities
  • Member of the executive board of Northern Institute for Cancer Research
  • RA representative to senior staff meetings.
  • Lab tissue culture co-ordinator
  • Establishing and running Imagestream/CTC research group.


  • British Association of Cancer Research


Research interests
  • Investigation, development and validation of biomarkers for pharmacodynamic endpoints in early phase clinical trials.
  • Establishment of methods to detect circulating tumour cells.
  • Imaging flow cytometry and quantitative image analysis.
  • Pharmacogenetics.


Grants received
  • AV Boddy, D Jamieson, KKN Chan. Relationship between genotype and reductase enzyme activity in bladder and ovarian tumours. July 2007-August 2007, Nuffield Science Bursaries Undergraduate Research. £1360 awarded
  • D Jamieson, FEB May, AV Boddy. Application to JGWP for consumable money to investigate NQO2 in kinase mediated signalling in breast cancer – 2008 to 2009, £16, 561 awarded
  • D Jamieson, AV Boddy, R Plummer. Capital costs for purchase of ImageStreamX imaging flow cytometer. Bobby Robson Foundation.  2012, £420,000 awarded
  • D Jamieson, AV Boddy, R Plummer , N Curtain, H Reeves, R Edmondson, C Robson, FEB May. Development of CTC assays. April 2012 to April 2013, NICR Pump Priming funds. £90,000 awarded.
  • AV Boddy, D Jamieson, J Dean.  June to July 2013. Welcome Trust Biomedical Vacation Scholarship. £1440 awarded.
  • FEB May, D Jamieson, SM Griffin. Prognostic, predictive and pharmacodynamic value of circulating tumour cells in oesophagogastric cancer patients in receipt of palliative systemic therapy. November 2013 to November 2015. JGWP Foundation. £46,136 awarded.
  • UK Mallick, V Paleri, GJ Veal, P Perros, TWJ Lennard, ER Plummer, D Jamieson. Feasibility of detection and enumeration of Circulating Tumour Cells in Thyroid Cancer using the Veridex LLC (Cell-Search) and the ImageStreamX Mark II (Amnis) flow cytometry methods – A Newcastle-Manchester joint pilot study. December 2014 to December 2016. Newcastle Healthcare Charity. £30,479 awarded.
  • GJ Veal, D Jamieson.  Pharmacogenetics of Doxorubicin, Gemcitabine and Docetaxel in Patients studied on the GeDDiS trial. 2015. Sarcoma UK. £22,317 awarded.


Teaching responsibilities
  • Undergraduate lecture on the use of alkylating agents in cancer chemotherapy.
  • Joint module leader on Oncology and Palliative Care MSc: Pharmacology of Anticancer Drugs
  • Supervision of undergraduates, masters and PhD students.